RetaMaps

Kashif Anwar, MD

Kashif Anwar, MD · 51 Scotch Road · Ewing Township, NJ 08628

2.0· 4 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss
  • Endocrine / metabolic care

About this practice

Kashif Anwar, MD is a physician in Ewing Township, New Jersey, listed for weight-loss care and endocrinology; the listing points to the Capital Health physician directory. Google shows a 2.0-star rating across 4 reviews dating back to 2024, with 2 in the past year, and reviewers mention the staff, the physician's knowledge and a caring manner.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 2.0
Google rating · 4 reviews
2
reviews in the past year (avg ★ 1.0)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-18. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★2.0 across 4 Google reviews. Of the 4 reviews we analyzed, 1 (25%) are positive (4–5★) and 3 (75%) are negative (1–2★).

What patients like

Not enough detailed reviews to summarize.

Common complaints

Very few complaints — only 3 negative reviews, with no recurring theme.

5★
1
4★
0
3★
0
2★
0
1★
3

Most recent Google reviews

joe★★★★★2026-09-18

Nice guy, but to busy to refill a script at right dosage. After month and a half of messages and requests from myself and other staff within his office. He would open messages and not even acknowledge them

valerie y.★★★★★2024-04-24

Dr.Anwar refused to see a patient today who was approximately six mins late and whom had traveled from PA. I have never experienced such dismissiveness and coldness from an office. Most doctors give you a 15 minute courtesy not that one makes a habit of being late. However, the patient was there for an urgent matter and this doctor just dismissed this patient. Bedside manner and customer service is still important and what happened to caring for your patients. Highly disappointed and a major turn off. This is definitely not treating a person, how you would like to be treated.

Chrissy M.★★★★★2024-04-01

Dr. Anwar and his staff are the absolute best!

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Clinicians

  • Kashif Anwar, MD

Nearby providers in Ewing Township

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs